ClinicalTrials.gg
CompletedNCT01194258Updated Aug 20, 2014Results posted

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus

A Phase 2 interventional study of Insulin lispro and Insulin aspart in Diabetes Mellitus, Type II, sponsored by Halozyme Therapeutics. Completed at 22 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-20.

Sponsored by Halozyme Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Insulin Lispro · Diabetes Mellitus, Type 2.

Enrollment
18th of 36
132 · median 127
Started
2010
with 2 others
Phase 2
2 of 36
none open now
Registered
15th of 36
by date
Lead sponsor
2 of 36
Halozyme Therapeutics

Among the 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2, this one is the 18th largest by enrollment, is one of 3 that started in 2010, is one of 2 in phase 2, and was the 15th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About Insulin Lispro

Insulin Lispro: first FDA approval 1996 (HUMALOG KWIKPEN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The purpose of the study was to compare Humalog (insulin lispro)-recombinant human hyaluronidase PH20 (rHuPH20) or Novolog (insulin aspart)-rHuPH20 to insulin lispro for the treatment of Type 2 diabetes mellitus (T2DM) in basal-bolus therapy.

Read the detailed description

Criteria for randomization into the study included 1) fasting blood glucose and pre-dinner glucose values in the range of 70 to 140 milligrams per deciliter (mg/dL) approximately 60% of the time for 7 days prior to randomization; 2) 90 minute or 2-hour postprandial blood glucose \<220 mg/dL approximately 70% of the time for 7 days prior to randomization; and 3) successfully completing 3 days of 10-point glucose monitoring and have at least 4 self-monitored blood glucose values on all non-10-point monitoring days. Participants that did not meet 1 or more of these criteria during a 4- to 6-week Titration Period were not randomized.

03

Conditions studied

  • Diabetes Mellitus, Type II

Keywords

  • Type 2 diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females ≥18 years
  • Type 2 diabetes mellitus (T2DM) treated with insulin ≥12 months and prandial insulin (at least 2 meals per day) for ≥2 months
  • (BMI) of 23.0 to 45.0 kilograms per meter squared (kg/m\^2)
  • Glycosylated () level 7.0 to 8.5%, inclusive
  • Fasting C-peptide \<0.6 nanograms per milliliter (ng/mL)
  • Willingness to use insulin glargine twice a day as basal insulin for the duration of the study
  • Willingness to avoid use of an insulin infusion pump or unblinded continuous glucose monitoring (CGM) during the study

Exclusion criteria

Exclusion Criteria:

  • Known or suspected allergy to any component of any of the study drugs
  • Exclusive use of pre-mixed insulins
  • Use of pramlintide, exenatide, and/or liraglutide within 30 days of screening
  • Use of sulfonylureas within two months of screening
  • Use of drugs (such as or antimetabolites) that could interfere with the interpretation of study results or are known to cause interference with insulin action, glucose utilization, or recovery from hypoglycemia, during the study or within 30 days of screening
  • Recurrent severe hypoglycemia (more than 2 episodes over the last 6 months) or hypoglycemic unawareness, as judged by the investigator
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
132 participants (actual)

Study arms

  • Experimental
    Lispro-PH20/Insulin lispro

    All enrolled participants underwent a titration period of 4 to 6 weeks in which they received 100 units per milliliter (U/mL) insulin glulisine, injected subcutaneously (SC), pre-meals, with doses titrated to each participant individually. Next, participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle. Lispro-PH20 (Treatment A): 100 U/mL insulin lispro with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20 (rHuPH20) (combined: Lispro-PH20), injected SC, pre-meals, with doses titrated to each participant individually. Insulin Lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, with doses titrated to each participant individually. Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine.

    Drug: Insulin lispro · Drug: Recombinant human hyaluronidase PH20 · Drug: Insulin glulisine · Drug: Insulin glargine

  • Experimental
    Aspart-PH20/Insulin Lispro

    All enrolled participants underwent a titration period of 4 to 6 weeks in which they received 100 U/mL insulin glulisine, injected SC, pre-meals, with doses titrated to each participant individually. Next participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle. Aspart-PH20 (Treatment A): 100 U/mL insulin aspart with 5.0 µg/mL rHuPH20 (combined: Aspart-PH20), injected SC, pre-meals, with doses titrated to each participant individually. Insulin lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, with doses titrated to each participant individually. Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine.

    Drug: Insulin lispro · Drug: Insulin aspart · Drug: Recombinant human hyaluronidase PH20 · Drug: Insulin glulisine · Drug: Insulin glargine

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycosylated Hemoglobin A1C (HbA1C) at the End of Each Treatment Period

    Change in glycosylated hemoglobin A1C (HbA1C) from baseline (Week 0) to end of treatment period (Week 12 and Week 24) is presented. Data are presented by combined treatment group (Lispro-recombinant human hyaluronidase PH20 (PH20) + Aspart-PH20 = Analog-PH20) and combined comparator drug (Insulin lispro from both groups). Least squares (LS) means were calculated from linear contrasts of mixed effects linear models with treatment (Lispro, Aspart), PH20 (yes, no), and treatment sequence as fixed effects and participant within treatment sequence as a random effect.

    Time frame: Baseline, Week 12 and Week 24

Secondary outcomes

  1. Mean Daily Insulin Dose as Recorded During 10-Point Glucose Monitoring

    Mean daily insulin dose as recorded during 10-point glucose monitoring is reported. Blood glucose values were obtained during a total of 3 days during each treatment period (3 days during Week 10 of Treatment Period 1 and 3 days during Week 22 of Treatment Period 2) at the following timepoints: immediately prior to breakfast (fasting), 1 hour (hr) after breakfast, 2 hr after breakfast, immediately prior to lunch, 1 hr after lunch, 2 hr after lunch, immediately prior to dinner, 1 hr after dinner, 2 hr after dinner, and at 03:00. A minimum of 7 determinations were required for each day during the 3 days of 10-point glucose profiles. Prandial insulin doses were also recorded during the 10-point glucose monitoring and the mean daily insulin dose over the 3 days was calculated. Data are presented by combined treatment group (Lispro-PH20 + Aspart-PH20 = Analog-PH20) and combined comparator drug (Insulin Lispro from both cohorts).

    Time frame: Week 10 and Week 22

  2. Percentage of Participants Meeting Glucose Targets at Least 2/3 of the Time

    Participants were instructed to monitor their blood glucose levels a minimum of 4 times per day on all non-10-point glucose monitoring days. The number of participants meeting 90-minute postprandial plasma glucose (PPG) targets of \<140 and \<180 milligrams per deciliter (mg/dL) for at least 2/3 of values was recorded during non-10-point glucose monitoring was recorded. The number of participants was recorded, and the percentage of participants meeting glucose targets was calculated by the number of participants with values meeting the specified target at least 2/3 of the time by the total number of participants analyzed, multiplied by 100. Data is presented by combined treatment group (Lispro-PH20 + Aspart-PH20 = Analog-PH20) and combined comparator drug (Insulin Lispro from both cohorts).

    Time frame: Baseline through Week 24, excluding 10-point glucose monitoring days

  3. Rates of Hypoglycemia at the End of Each Treatment Period

    The rate of hypoglycemia, defined as blood glucose levels ≤70 mg/dL and \<56 mg/dL, was calculated based on 4 weeks of observation prior to the end of treatment period (that is, Week 12 and Week 24). Data are presented by combined treatment group (Lispro-PH20 + Aspart-PH20 = Analog-PH20) and combined comparator drug (Insulin lispro from both groups). A summary of serious and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

    Time frame: Week 12 and Week 24

  4. Change From Baseline in Body Weight at the End of Each Treatment Period

    Change from baseline in body weight at the end of each treatment period (Week 12 and Week 24) is presented. Data are presented by combined treatment group (Lispro-PH20 + Aspart-PH20 = Analog-PH20) and combined comparator drug (Insulin lispro from both cohorts).

    Time frame: Baseline, Week 12 and Week 24

  5. Mean Daily PPG Excursions

    Participants performed 10-point glucose monitoring for a total of 3 days during each treatment period (3 days during Week 10 of Treatment Period 1 and 3 days during Week 22 of Treatment Period 2). Mean daily PPG excursions during 10-point glucose monitoring for breakfast, lunch, and dinner from Treatment Period 1 or Treatment Period 2 are presented. PPG refers to the change in glucose concentration before to after a meal. Data were collected 1 and 2 hours (hr) after each meal. Data are presented by combined treatment group (Lispro-PH20 + Aspart-PH20 = Analog-PH20) and combined comparator drug (insulin lispro from both cohorts).

    Time frame: Week 10 and Week 22

07

Results

Posted Aug 20, 2014

Participant flow

Titration Period
Participant flow — Titration Period
MilestoneAll Enrolled ParticipantsInsulin Lispro, Then Lispro-PH20Lispro-PH20, Then Insulin LisproInsulin Lispro, Then Aspart-PH20Aspart-PH20, Then Insulin Lispro
Started1320000
Completed1210000
Not completed110000
Withdrew: Withdrawal by subject60000
Withdrew: Lost to follow-up20000
Withdrew: Titration failure30000
Period 1 (12 Weeks)
Participant flow — Period 1 (12 Weeks)
MilestoneAll Enrolled ParticipantsInsulin Lispro, Then Lispro-PH20Lispro-PH20, Then Insulin LisproInsulin Lispro, Then Aspart-PH20Aspart-PH20, Then Insulin Lispro
Started029302933
Received at least 1 dose of study drug029302933
Completed029302932
Not completed00001
Withdrew: Death00001
Period 2 (12 Weeks)
Participant flow — Period 2 (12 Weeks)
MilestoneAll Enrolled ParticipantsInsulin Lispro, Then Lispro-PH20Lispro-PH20, Then Insulin LisproInsulin Lispro, Then Aspart-PH20Aspart-PH20, Then Insulin Lispro
Started029302932
Completed027292930
Not completed02102
Withdrew: Lost to follow-up00002
Withdrew: Adverse event01000
Withdrew: Withdrawal by subject01100

Outcome measures

PrimaryChange From Baseline in Glycosylated Hemoglobin A1C (HbA1C) at the End of Each Treatment Period

Change in glycosylated hemoglobin A1C (HbA1C) from baseline (Week 0) to end of treatment period (Week 12 and Week 24) is presented. Data are presented by combined treatment group (Lispro-recombinant human hyaluronidase PH20 (PH20) + Aspart-PH20 = Analog-PH20) and combined comparator drug (Insulin lispro from both groups). Least squares (LS) means were calculated from linear contrasts of mixed effects linear models with treatment (Lispro, Aspart), PH20 (yes, no), and treatment sequence as fixed effects and participant within treatment sequence as a random effect.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · percentage of HbA1C
Change From Baseline in Glycosylated Hemoglobin A1C (HbA1C) at the End of Each Treatment Period
percentage of HbA1CAnalog-PH20Insulin Lispro
Change From Baseline in Glycosylated Hemoglobin A1C (HbA1C) at the End of Each Treatment Period-0.48 ± 0.590-0.46 ± 0.571
Statistical analysis
  • Analog-PH20 vs Insulin Lispro · Mixed Models Analysis · p = 0.3876 · Ls mean difference: -0.04 · 95% CI -0.12 to 0.05
SecondaryMean Daily Insulin Dose as Recorded During 10-Point Glucose Monitoring

Mean daily insulin dose as recorded during 10-point glucose monitoring is reported. Blood glucose values were obtained during a total of 3 days during each treatment period (3 days during Week 10 of Treatment Period 1 and 3 days during Week 22 of Treatment Period 2) at the following timepoints: immediately prior to breakfast (fasting), 1 hour (hr) after breakfast, 2 hr after breakfast, immediately prior to lunch, 1 hr after lunch, 2 hr after lunch, immediately prior to dinner, 1 hr after dinner, 2 hr after dinner, and at 03:00. A minimum of 7 determinations were required for each day during the 3 days of 10-point glucose profiles. Prandial insulin doses were also recorded during the 10-point glucose monitoring and the mean daily insulin dose over the 3 days was calculated. Data are presented by combined treatment group (Lispro-PH20 + Aspart-PH20 = Analog-PH20) and combined comparator drug (Insulin Lispro from both cohorts).

Time frame:
Week 10 and Week 22
Reported as:
Mean · units of Insulin
Mean Daily Insulin Dose as Recorded During 10-Point Glucose Monitoring
units of InsulinAnalog-PH20Insulin Lispro
Mean Daily Insulin Dose as Recorded During 10-Point Glucose Monitoring122.99 ± 67.150127.47 ± 69.483
SecondaryPercentage of Participants Meeting Glucose Targets at Least 2/3 of the Time

Participants were instructed to monitor their blood glucose levels a minimum of 4 times per day on all non-10-point glucose monitoring days. The number of participants meeting 90-minute postprandial plasma glucose (PPG) targets of \<140 and \<180 milligrams per deciliter (mg/dL) for at least 2/3 of values was recorded during non-10-point glucose monitoring was recorded. The number of participants was recorded, and the percentage of participants meeting glucose targets was calculated by the number of participants with values meeting the specified target at least 2/3 of the time by the total number of participants analyzed, multiplied by 100. Data is presented by combined treatment group (Lispro-PH20 + Aspart-PH20 = Analog-PH20) and combined comparator drug (Insulin Lispro from both cohorts).

Time frame:
Baseline through Week 24, excluding 10-point glucose monitoring days
Reported as:
Number · Percentage of participants
Percentage of Participants Meeting Glucose Targets at Least 2/3 of the Time
Percentage of participantsAnalog-PH20Insulin Lispro
Overall 90-minute PPG <140 mg/dL13.914.8
PPG <140 mg/dL for breakfast24.317.4
PPG <140 mg/dL for lunch28.726.1
PPG <140 mg/dL for dinner13.015.7
Overall 90 minute PPG <180 mg/dL71.374.8
PPG <180 mg/dL for breakfast70.465.2
PPG <180 mg/dL for lunch83.580.0
PPG <180 mg/dL for dinner67.070.4
SecondaryRates of Hypoglycemia at the End of Each Treatment Period

The rate of hypoglycemia, defined as blood glucose levels ≤70 mg/dL and \<56 mg/dL, was calculated based on 4 weeks of observation prior to the end of treatment period (that is, Week 12 and Week 24). Data are presented by combined treatment group (Lispro-PH20 + Aspart-PH20 = Analog-PH20) and combined comparator drug (Insulin lispro from both groups). A summary of serious and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

Time frame:
Week 12 and Week 24
Reported as:
Number · Events per participant per month
Rates of Hypoglycemia at the End of Each Treatment Period
Events per participant per monthAnalog-PH20Insulin Lispro
Blood glucose <70 mg/dL (n=111, n=113)7.927.66
Blood glucose <56 mg/dL (n=91, n=86)1.991.78
SecondaryChange From Baseline in Body Weight at the End of Each Treatment Period

Change from baseline in body weight at the end of each treatment period (Week 12 and Week 24) is presented. Data are presented by combined treatment group (Lispro-PH20 + Aspart-PH20 = Analog-PH20) and combined comparator drug (Insulin lispro from both cohorts).

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · pounds
Change From Baseline in Body Weight at the End of Each Treatment Period
poundsAnalog-PH20Insulin-lispro
Change From Baseline in Body Weight at the End of Each Treatment Period3.35 ± 5.4663.44 ± 5.852
SecondaryMean Daily PPG Excursions

Participants performed 10-point glucose monitoring for a total of 3 days during each treatment period (3 days during Week 10 of Treatment Period 1 and 3 days during Week 22 of Treatment Period 2). Mean daily PPG excursions during 10-point glucose monitoring for breakfast, lunch, and dinner from Treatment Period 1 or Treatment Period 2 are presented. PPG refers to the change in glucose concentration before to after a meal. Data were collected 1 and 2 hours (hr) after each meal. Data are presented by combined treatment group (Lispro-PH20 + Aspart-PH20 = Analog-PH20) and combined comparator drug (insulin lispro from both cohorts).

Time frame:
Week 10 and Week 22
Reported as:
Mean · mg/dL
Mean Daily PPG Excursions
mg/dLAnalog-PH20Insulin Lispro
1 hr after breakfast excursion (n=105, n=107)33.67 ± 34.48040.38 ± 30.213
2 hr after breakfast excursion (n=105, n=107)16.64 ± 40.46322.94 ± 33.514
1 hr after lunch excursion (n=105, n=106)18.47 ± 35.41927.28 ± 30.075
2 hr after lunch excursion (n=104, n=106)20.76 ± 38.93925.27 ± 34.288
1 hr after dinner excursion (n=104, n=107)21.24 ± 32.80718.09 ± 28.869
2 hr after dinner excursion (n=104, n=107)12.72 ± 35.91715.75 ± 36.104

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Titration Period—2/132 (1.5%)34/132 (25.8%)
Insulin Lispro (Lispro-PH20 Cohort)—0/59 (0%)19/59 (32.2%)
Lispro-PH20—0/59 (0%)29/59 (49.2%)
Insulin Lispro (Aspart-PH20 Cohort)—1/60 (1.7%)32/60 (53.3%)
Aspart-PH20—4/62 (6.5%)35/62 (56.5%)
Most frequent serious events
Most frequent serious events
EventTitration PeriodInsulin Lispro (Lispro-PH20 Cohort)Lispro-PH20Insulin Lispro (Aspart-PH20 Cohort)Aspart-PH20
Acute myocardial infarctionCardiac disorders0/1320/590/590/602/62
Cardiac failure congestiveCardiac disorders0/1320/590/590/602/62
Transient ischemic attackNervous system disorders0/1320/590/591/600/62
Angina unstableCardiac disorders0/1320/590/590/601/62
Partial seizuresNervous system disorders0/1320/590/590/601/62
DyspepsiaGastrointestinal disorders1/1320/590/590/600/62
Anaphylactic reactionImmune system disorders1/1320/590/590/600/62
Most frequent other events
Showing 10 of 132
Most frequent other events
EventTitration PeriodInsulin Lispro (Lispro-PH20 Cohort)Lispro-PH20Insulin Lispro (Aspart-PH20 Cohort)Aspart-PH20
Upper respiratory tract infectionInfections and infestations6/1324/597/597/603/62
NasopharyngitisInfections and infestations2/1322/593/597/604/62
DiarrhoeaGastrointestinal disorders3/1320/595/592/602/62
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/530/100/100/141/15
ArthralgiaMusculoskeletal and connective tissue disorders1/1320/590/590/604/62
HeadacheNervous system disorders1/1322/590/592/604/62
NauseaGastrointestinal disorders1/1321/593/593/602/62
GastroenteritisInfections and infestations0/1320/590/593/602/62
Pain in extremityMusculoskeletal and connective tissue disorders1/1321/590/593/602/62
VomitingGastrointestinal disorders0/1320/592/592/601/62

Baseline characteristics

All participants in the study, including those who were enrolled but were not randomized.

Age, Continuous
Age, Continuous(years)All Study Participants
Mean58.7 ± 9.85
Sex: Female, Male
Sex: Female, Male(Participants)All Study Participants
Female53
Male79
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Study Participants
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander1
Black or African American10
White115
More than one race1
Unknown or Not Reported2
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Study Participants
Hispanic or Latino19
Not Hispanic or Latino113
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)All Study Participants
United States132
08

Study locations

22 sites
  • John Muir Physician Network Clinical Research Center
    Concord, California 94520, United States
  • Medical Group of Encino
    Encino, California 91436, United States
  • AMCR Institute, Inc.
    Escondido, California 92026, United States
  • Marin Endocrine Care and Research
    Greenbrae, California 94904, United States
  • Mills-Peninsula Health Services
    San Mateo, California 94401, United States
  • Center for Diabetes and Endocrine Care
    Hollywood, Florida 33021, United States
  • Diabetes Research Institute
    Miami, Florida 33136, United States
  • Baptist Diabetes Associates
    Miami, Florida 33156, United States
  • Rocky Mountain Diabetes and Osteoporosis Center
    Idaho Falls, Idaho 83404, United States
  • Mid-America Diabetes Associates
    Wichita, Kansas 67211, United States
  • Tulane University Health Sciences Center
    New Orleans, Louisiana 70112, United States
  • Medstar Research Institute
    Hyattsville, Maryland 20782, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • International Diabetes Center
    Minneapolis, Minnesota 55416, United States
  • Mercury Street Medical
    Butte, Montana 59701, United States
  • Desert Endocrinology
    Henderson, Nevada 89052, United States
  • Diabetes and Endocrinology Associates, PC
    Morehead, North Carolina 28557, United States
  • UT Southwestern Medical Center at Dallas
    Dallas, Texas 75390, United States
  • Texas Diabetes and Endocrinology
    Round Rock, Texas 78681, United States
  • Cetero Research-San Antonio
    San Antonio, Texas 78229, United States
  • West Olympia Internal Medicine
    Olympia, Washington 98502, United States
  • University of Washington School of Medicine
    Seattle, Washington 98105, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2010
First posted
Sep 2, 2010
Start
Aug 2010
Primary completionActual
Aug 2011
CompletionActual
Aug 2011
Results first posted
Aug 20, 2014
Last update
Aug 20, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01194258
Responsible party
Sponsor
First posted
Sep 2, 2010
Start date
Aug 2010
Primary completion
Aug 2011
Completion
Aug 2011
Results posted
Aug 20, 2014
Last update
Aug 20, 2014

Study contacts

Douglas Muchmore, M.D.
study director · Halozyme Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Lispro · Hyaluronidase (human recombinant)

Start the discussion